AXDX — Accelerate Diagnostics Income Statement
0.000.00%
Last trade - 00:00
- $18.61m
- $43.06m
- $12.06m
- 33
- 27
- 57
- 33
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.3 | 11.2 | 11.8 | 12.8 | 12.1 |
Cost of Revenue | |||||
Gross Profit | 4.4 | 4.46 | 4.12 | 3.3 | 3.73 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 82.1 | 74.9 | 73.5 | 72 | 79.3 |
Operating Profit | -72.8 | -63.7 | -61.8 | -59.2 | -67.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -84.4 | -78.2 | -77.7 | -62.6 | -60.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -84.3 | -78.2 | -77.7 | -62.5 | -61.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -84.3 | -78.2 | -77.7 | -62.5 | -61.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -84.3 | -78.2 | -77.7 | -62.5 | -61.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -15.5 | -14 | -13.1 | -7.89 | -4.19 |